公司里程碑事件 - 新墨西哥心脏医院成为首个使用VIVO系统完成200例心室消融手术的客户 [1] - 该医院团队已发布临床数据并接待其他医生进行技术交流 [3] 产品技术优势 - VIVO系统是非侵入性3D成像系统 可术前定位心室心律失常起源点 [4] - 该技术能优化临床工作流程并缩短手术时间 [4] - 产品已获得美国FDA上市许可和CE认证标志 [4] 医疗机构背景 - 新墨西哥心脏医院隶属于Lovelace健康系统 拥有5家医院和33家医疗诊所 [2] - 该院是新墨西哥州唯一专注于心血管护理的专科医院 [2] - 医疗系统拥有超过300名医疗保健提供者 [2] 公司业务定位 - catheter precision是美国创新医疗器械公司 专注于心脏电生理领域 [5] - 公司通过与医生合作持续推动产品技术升级 [5] - 致力于为心律失常治疗提供新型解决方案 [5]

S-1/A 1 rmed_s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on August 26, 2024 Registration No. 333-279930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) David Jenkins Executive Chairman of the Board and Chief Executive Officer Catheter Precision, Inc. 1670 Highway 160 West, Suite 205 Fort Mill, S ...

S-1/A 1 rmed_s1.htm FORM S-1/A As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. 333-279930 Identification Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 38-3661826 (Primary Standard Industrial Classif ...

S-1 1 rmed_s1.htm FORM S-1 As filed with the Securities and Exchange Commission on June 3, 2024 Registration No. 333-__________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 38-3661826 (Primary Standard Industrial Classification Code Number) (I.R.S ...